Skip to search formSkip to main contentSkip to account menu

PLX4032

Known as: B-Raf inhibitor PLX4032, PLX 4032, PLX-4032 
National Institutes of Health

Related topics

Related topics

2 relations
RG7204

Broader (1)

Vemurafenib

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2015
2015
Kinase inhibitor screening identifies CDK4 as a potential therapeutic target for melanoma
Despite recent advances in targeted therapies and immunotherapies metastatic melanoma remains only rarely curable. The objective… 
2013
2013
Vemurafenib (PLX4032, Zelboraf®), a BRAF Inhibitor, Modulates ABCB1-, ABCG2-, and ABCC10-Mediated Multidrug Resistance
In this study, we examined the in vitro effects of vemurafenib, a specific inhibitor of V600E mutated BRAF enzyme, on the… 
2012
2012
An open-label, multicenter safety study of vemurafenib (PLX4032, RO5185426) in patients with metastatic melanoma.
8517 Background: Vemurafenib, a BRAF inhibitor, is associated with improved PFS and OS in patients (pts) with BRAFV600-mutant… 
2011
2011
Molecular analyses from a phase I trial of vemurafenib to study mechanism of action (MOA) and resistance in repeated biopsies from BRAF mutation-positive metastatic melanoma patients (pts).
8502 Background: Vemurafenib (PLX4032), an oral, selective inhibitor of oncogenic V600E mutant BRAF, was evaluated for safety and… 
2011
2011
Parsing out the complexity of RAF inhibitor resistance
The discovery in 2002 of frequent mutation of BRAF in cancer was a milestone event in our understanding of the genetics of… 
2011
2011
Dual fronts poised to transform melanoma therapy
With recent successes of immunotherapies and targeted drugs, melanoma has become one of the most dynamic areas of anticancer drug… 
2010
2010
PLX4032 (RG7204), a selective mutant RAF inhibitor: Clinical and histologic characteristics of therapy-associated cutaneous neoplasms in a phase I trial.
8592 Background: Tumor regressions have been observed in a significant proportion of advanced melanoma patients treated with… 
2009
2009
PLX4032, a highly selective V600EBRAF kinase inhibitor: Clinical correlation of activity with pharmacokinetic and pharmacodynamic parameters in a phase I trial.
9021 Background: PLX4032 is an oral, highly selective inhibitor of oncogenic V600EBRAF kinase currently in phase I trial… 
2008
2008
Effect of Interleukin-2 Pretreatment on Paclitaxel Absorption and Tissue Disposition after Oral and Intravenous Administration in Mice
The aim of the present study was to investigate the effects of recombinant interleukin (rIL)-2 treatment on paclitaxel (PLX… 
2007
2007
Plx4032, a selective b-rafV600E inhibitor has potent anti-tumor activity in b-rafV600E-bearing colorectal xenografts and shows additive effect with other chemoagents
A252 The Ras-Raf-MEK-ERK signaling pathway plays a critical role in many aspects of human tumorigenesis. B-Raf mutations have… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)